Research
Hormonal
Incretin-based glucose-lowering medications, including DPP-4 inhibitors and GLP-1 receptor agonists, open new perspectives in the treatment of type 2 diabetes.
Practitioners should consider incretin-based therapies as viable options for managing type 2 diabetes.
StrongSupportsmedium confidence
Az inkretinhatáson alapuló vércukorcsökkentők, a dipeptidil-peptidáz-gátlók és a glükagonszerű peptid-1-receptor-agonisták (GLP-1 RA-k) bevezetése új távlatokat nyitott a 2-es típusú cukorbetegség antidiabetikus kezelésében.
Why this rating
The claim is based on established medications and their recognized effects.
Source
Kettős inkretinterápia – új lehetőség a 2-es típusú diabetes vércukorcsökkentő kezelésében
Gábor Winkler et al. · Lege Artis Medicinae · 2022
DOI 10.33616/lam.32.019
reviewCited 1×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →